Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR

Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conv...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2020-09, Vol.12 (10), p.937
Main Authors: Pothin, Elodie, Lesuisse, Dominique, Lafaye, Pierre
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Biotechnology
blood–brain barrier (BBB)
drug delivery
Insulin
Insulin-like growth factors
Life Sciences
Molecular weight
Proteins
Review
single-domain antibody
variable domain of heavy-chain antibody (VHH)
variable new antigen receptor (VNAR)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conventional antibodies is their limited brain penetration because of the blood-brain barrier (BBB). In this review, we aim at exploring the different options single-domain antibodies (sDAbs) such as variable domain of heavy-chain antibodies (VHHs) and variable new antigen receptors (VNARs) have already taken to reach the brain allowing them to be used as therapeutic, diagnosis or transporter tools.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics12100937